Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junbao Liu

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Gels (Basel, Switzerland)|February 26, 2026
Highly Efficient Elimination of As(V) and As(III) from Aqueous Media Utilizing Fe-Ti-Mn/Chitosan Composite Xerogel BeadsChunting Chen, Junbao Liu, Hongpeng Cao, et al.
Frontiers in Medicine|February 7, 2022
Performance of Ultrasound-Guided Core Biopsy Driven by FDG-avid Supraclavicular Lymph Nodes in Patients With Suspected Lung CancerTongtong Wang, Junbao Liu, Ningning Lv, et al.
Scientific Reports|August 30, 2018
Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatmentYanchun Wang, Xuewei Liu, Xuemei Wang, et al.
International Immunopharmacology|January 18, 2025
Gut microbial metabolite indole-3-propionic acid alleviates polycystic ovary syndrome in mice by regulating the AhR-NLRP3 axisZhuohan Li, Huafeng Geng, Cong Ye, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 3, 2026
The current status and influencing factors of prophylactic antibacterial drug use in patients with hypertriglyceridemic acute pancreatitisPeitao Xie, Shuxin Jiao, Junbao Liu, et al.
Investigational New Drugs|July 11, 2024
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancerJing Zhang, Wenwei Yang, Junbao Liu, et al.
Oncology Letters|September 10, 2014
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancerChengxu Cui, Chang Shu, Yi Yang, et al.
Frontiers in Oncology|May 14, 2026
Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective studyJunbao Liu, Yuting Fang, Guifu Wu, et al.
Plos One|June 10, 2015
Identification of New Candidate Genes and Chemicals Related to Esophageal Cancer Using a Hybrid Interaction Network of Chemicals and ProteinsYu-Fei Gao, Fei Yuan, Junbao Liu, et al.
Oncology Letters|November 30, 2016
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimensChengxu Cui, Chang Shu, Dandan Cao, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Gels (Basel, Switzerland)|February 26, 2026
Highly Efficient Elimination of As(V) and As(III) from Aqueous Media Utilizing Fe-Ti-Mn/Chitosan Composite Xerogel BeadsChunting Chen, Junbao Liu, Hongpeng Cao, et al.
Frontiers in Medicine|February 7, 2022
Performance of Ultrasound-Guided Core Biopsy Driven by FDG-avid Supraclavicular Lymph Nodes in Patients With Suspected Lung CancerTongtong Wang, Junbao Liu, Ningning Lv, et al.
Scientific Reports|August 30, 2018
Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatmentYanchun Wang, Xuewei Liu, Xuemei Wang, et al.
International Immunopharmacology|January 18, 2025
Gut microbial metabolite indole-3-propionic acid alleviates polycystic ovary syndrome in mice by regulating the AhR-NLRP3 axisZhuohan Li, Huafeng Geng, Cong Ye, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 3, 2026
The current status and influencing factors of prophylactic antibacterial drug use in patients with hypertriglyceridemic acute pancreatitisPeitao Xie, Shuxin Jiao, Junbao Liu, et al.
Investigational New Drugs|July 11, 2024
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancerJing Zhang, Wenwei Yang, Junbao Liu, et al.
Oncology Letters|September 10, 2014
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancerChengxu Cui, Chang Shu, Yi Yang, et al.
Frontiers in Oncology|May 14, 2026
Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective studyJunbao Liu, Yuting Fang, Guifu Wu, et al.
Plos One|June 10, 2015
Identification of New Candidate Genes and Chemicals Related to Esophageal Cancer Using a Hybrid Interaction Network of Chemicals and ProteinsYu-Fei Gao, Fei Yuan, Junbao Liu, et al.
Oncology Letters|November 30, 2016
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimensChengxu Cui, Chang Shu, Dandan Cao, et al.
Pageof 4